fleroxacin has been researched along with rifampin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Amyes, SG; Lewin, CS | 1 |
| Chuard, C; Herrmann, M; Lew, DP; Vaudaux, P; Waldvogel, FA | 1 |
| Auckenthaler, R; Chuard, C; Herrmann, M; Lew, DP; Lucet, JC; Rohner, P; Waldvogel, FA | 1 |
| Auckenthaler, R; Herrmann, M; Lew, DP; Lucet, JC; Rohner, P; Waldvogel, FA | 1 |
| Easmon, C; Verity, L | 1 |
| Pohlod, DJ; Saravolatz, LD; Somerville, MM | 1 |
| Dayer, P; Leemann, T; Lew, DP; Portmann, R; Schrenzel, J; Weidekamm, E | 1 |
| Ansorg, R; Fabry, W; Schmid, EN | 1 |
| Bregenzer, T; Flueckiger, U; Francioli, P; Genné, D; Harbarth, S; Jacobs, F; Lew, DP; Petignat, C; Schockmel, G; Schrenzel, J; Zimmerli, W | 1 |
1 trial(s) available for fleroxacin and rifampin
| Article | Year |
|---|---|
A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection.
Topics: Administration, Oral; Adult; Aged; Bacteremia; Catheters, Indwelling; Drug Therapy, Combination; Female; Fleroxacin; Floxacillin; Humans; Male; Methicillin Resistance; Middle Aged; Prospective Studies; Rifampin; Safety; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Treatment Outcome; Vancomycin | 2004 |
12 other study(ies) available for fleroxacin and rifampin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL 16.
Topics: Anti-Infective Agents; Bacterial Proteins; Chloramphenicol; Ciprofloxacin; Escherichia coli; Fleroxacin; Pefloxacin; Rifampin; RNA, Bacterial | 1990 |
Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations.
Topics: Animals; Cells, Cultured; Chronic Disease; Drug Interactions; Drug Therapy, Combination; Fleroxacin; Foreign-Body Reaction; Methicillin Resistance; Microbial Sensitivity Tests; Rats; Rats, Inbred Strains; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1991 |
Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Diffusion Chambers, Culture; Disease Models, Animal; Drug Resistance, Microbial; Fleroxacin; Foreign Bodies; Gentamicins; Kinetics; Microbial Sensitivity Tests; Oxacillin; Penicillin Resistance; Rats; Rats, Inbred Strains; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1991 |
Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Fleroxacin; Foreign-Body Reaction; Male; Methicillin Resistance; Microbial Sensitivity Tests; Rats; Rats, Inbred Strains; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1990 |
Effect of Ro 23-6240 on sensitive and resistant intracellular mycobacteria.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Fleroxacin; Humans; Macrophages; Mice; Mycobacterium; Nontuberculous Mycobacteria; Rifampin | 1987 |
Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin.
Topics: Anti-Infective Agents; Cefoxitin; Ciprofloxacin; Erythromycin; Fleroxacin; Humans; Legionella; Macrophages; Microbial Sensitivity Tests; Rifampin | 1988 |
Influence of rifampin on fleroxacin pharmacokinetics.
Topics: Adult; Anti-Bacterial Agents; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Induction; Fleroxacin; Humans; Hydrocortisone; Liver; Male; Rifampin; Staphylococcal Infections | 1993 |
Comparison of the E test and a proportion dilution method for susceptibility testing of Mycobacterium tuberculosis.
Topics: Amikacin; Antitubercular Agents; Ciprofloxacin; Clarithromycin; Fleroxacin; Fusidic Acid; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Streptomycin | 1995 |